Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Crossref DOI link: https://doi.org/10.1186/s12879-017-2803-0
Published Online: 2017-10-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sanchez-Luna, M.
Burgos-Pol, R.
Oyagüez, I.
Figueras-Aloy, J.
Sánchez-Solís, M.
Martinón-Torres, F.
Carbonell-Estrany, X.
Funding for this research was provided by:
Fundación Instituto para la Mejora de la Asistencia Sanitaria